Additionally, these drugs significantly inhibited the migration of KM12SM cells, suggesting that TRK inhibitors may suppress cancer progression by negatively regulating the NFκB pathway and positively regulating the NRF2 pathway [51]. This evidence concerns the gene TPM3 and cancer.